| Literature DB >> 2725701 |
J G Baird1, E R Chilvers, E D Kennedy, S R Nahorski.
Abstract
The effect of changes in extracellular calcium concentration ([Ca2+]e) on the incorporation of myo-[2-3H]-inositol into phosphoinositides and agonist-stimulated 3H-inositol phosphates (3H-InsPs) was examined in rat cerebral cortex and bovine tracheal smooth muscle slices. In brain slices, reduction in [Ca2+]e from 2.4 to 1.2 mmol/l resulted in an approximate doubling of the carbachol and noradrenaline-stimulated 3H-InsP response with no effect on the EC50 values. An identical effect of varying [Ca2+]e was observed for carbachol-stimulated 3H-InsP formation in tracheal smooth muscle with a further increase in 3H-InsPs evident at [Ca2+]e 0.6 mmol/l. In this tissue the effect of changes in [Ca2+]e on the incorporation of myo-[2-3H]-inositol into the total phosphoinositide pool directly paralleled the changes in 3H-InsPs except in conditions of no added calcium when 3H-InsP responses were markedly impaired. Additional studies in brain slices using buffer where the added calcium varied between 0 and 2.4 mmol/l, showed that both the carbachol stimulated formation of separate inositol phosphates during short incubation periods and incorporation of myo-[2-3H]-inositol into PtdInsP and PtdInsP2 under basal conditions was maximal at [Ca2+]e 0.3 mmol/l. Omitting Ca2+ from the buffer resulted in maximal labelling of PtdIns but a decrease in PtdInsP and PtdInsP2 labelling (compared with the level at [Ca2+]e 0.3 mmol/l) and a markedly impaired inositol polyphosphate response. Alterations in [Ca2+]e following 3H-inositol labelling but immediately prior to carbachol stimulation did not influence 3H-inositol polyphosphate responses. It is therefore clear that even relatively small changes in [Ca2+]e markedly influence agonist-stimulated 3H-InsP responses in brain and tracheal smooth muscle slices and that these reflect changes in the labelling of substrate inositol lipids.(ABSTRACT TRUNCATED AT 250 WORDS)Entities:
Mesh:
Substances:
Year: 1989 PMID: 2725701 DOI: 10.1007/bf00173572
Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN: 0028-1298 Impact factor: 3.000